DOT Changing Drug Testing to Address Opioid Abuse Epidemic
The Department of Transportation plans to add four prescription opioids – hydrocodone, hydromorphone, oxymorphone and oxycodone – to the existing DOT drug-testing panel for screening truck drivers and other "safety-sensitive" transportation workers. This final rule is to take effect on Jan. 1.
The Department of Transportation plans to add four prescription opioids – hydrocodone, hydromorphone, oxymorphone and oxycodone – to the existing DOT drug-testing panel for screening truck drivers and other "safety-sensitive" transportation workers. The change is part of a final rule to take effect on Jan. 1.
“Inclusion of these four semi-synthetic opioids is intended to help address the opiod epidemic,” DOT said in its rulemaking notice, which is to be published in the Federal Register for Nov. 13.
Ad Loading...
The agency noted that these four drugs that are “already tested for in many transportation employers' non-DOT testing programs because of their widespread use and potentially impairing effect" and that adding them to the required screening will allow DOT to detect a broader range of drugs being used illegally.
The final rule also adds the drug methylenedioxyamphetamine as an initial test analyte and removes the drug methylenedioxyethylamphetamine as a confirmatory test analyte. In addition, the rule does away with the requirement for employers and consortium/third-party administrators to submit blind specimens.
The agency said that the revisions to 49 CFR Part 40 will harmonize DOT regulations with revised Department of Health and Human Services "mandatory guidelines" for federal drug-testing programs for urine testing.
The rule had originally been proposed in January of this year. DOT said it received 52 comments on the addition of the four semi-synthetic opioids to the testing panel. Of those, 41 supported the revision. The agency said those supporters “generally recognized the need for the department to act consistently with the HHS Mandatory Guidelines and agreed that addressing opioid abuse issues in the context of transportation safety is important.”
As for the other 11 comments, DOT said they essentially contended that adding the substances would “increase circumstances in which drivers innocently using opioids (e.g., via a prescription for pain medication) would be unfairly treated as drug abusers, with consequent positive tests harming their careers.”
Ad Loading...
And a few comments suggested adding still other substances, such as methadone or synthetic cannabinoids, to the panel.
Distracted driving remains one of the most persistent risks in fleet operations. New approaches focus on removing mobile device use entirely while adding real-time safety support.
As distraction risks evolve, fleets are turning to smarter, more connected technologies to better understand what’s happening behind the wheel. Part 2 explores how these tools are helping identify risky behaviors and improve visibility across operations.
Distracted driving is often measured by what we can see—phones in hand, eyes off the road. But what about the distractions we can’t? A recent incident raises a bigger question about awareness, attention, and why subtle risks so often go unnoticed.
Fleets have more driver data than ever, so why isn't behavior changing? Training requires more than reports and coaching — it requires real-world practice.
A two-part conversation with Stefan Heck on how AI is transforming the fight against distracted driving. As fleets adopt smarter tools, the focus shifts from reacting to preventing risk. In Part 1, we look at where AI is making an impact for fleets today.
An 11% drop in pedestrian fatalities in early 2025 signals progress in U.S. road safety, but elevated death rates and ongoing risks underscore the need for continued action from fleets and policymakers.
